Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL and Toripalimab in Stage IIIB-IV NSCLC
NCT04193098Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic adenovirus-specific cytotoxic T lymphocytes in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
allogeneic adenovirus-specific cytotoxic T lymphocytes
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04193098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193098.